MEDP
Medpace Holdings Inc.
Company Overview
| Mkt Cap | $15.47B | Price | $460.20 |
| Volume | 472.74K | Change | +0.68% |
| P/E Ratio | 34.3 | Open | $463.05 |
| Revenue | $2.5B | Prev Close | $457.09 |
| Net Income | $451.1M | 52W Range | $294.07 - $628.92 |
| Div Yield | N/A | Target | $453.18 |
| Overall | 67 | Value | -- |
| Quality | 63 | Technical | 72 |
No chart data available
About Medpace Holdings Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Latest News
Pritelivir Trial Update Highlights Medpace’s Role in Drug-Resistant HSV Market
Pritelivir Trial Update Highlights Medpace’s Role in Drug-Resistant HSV Market
Medpace Elevates Brad Hansman to Executive Operations Role
BEACON Phase III Rugonersen Trial Puts Medpace in Focus for Rare Disease Investors
BEACON Phase III Rugonersen Trial Puts Medpace in Focus for Rare Disease Investors
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MEDP | $460.20 | +0.7% | 472.74K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |